A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of
Official title: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P25/28 (Drugs for disorders of the nervous system: for treating neurodegenerative disorders of) appears on 30,340 US grants and 47,332 published applications in this corpus.
Search patents in A61P- Granted patents
- 30,340
- Published applications
- 47,332
- Assignees
- 9,658
- Inventors
- 63,752
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 6 | 0 |
| 1979 | 6 | 0 |
| 1980 | 8 | 0 |
| 1981 | 8 | 0 |
| 1982 | 9 | 0 |
| 1983 | 10 | 0 |
| 1984 | 15 | 0 |
| 1985 | 20 | 0 |
| 1986 | 29 | 0 |
| 1987 | 38 | 0 |
| 1988 | 46 | 0 |
| 1989 | 76 | 0 |
| 1990 | 83 | 0 |
| 1991 | 111 | 0 |
| 1992 | 109 | 0 |
| 1993 | 108 | 0 |
| 1994 | 111 | 0 |
| 1995 | 133 | 0 |
| 1996 | 175 | 0 |
| 1997 | 297 | 0 |
| 1998 | 327 | 0 |
| 1999 | 328 | 0 |
| 2000 | 394 | 0 |
| 2001 | 498 | 152 |
| 2002 | 596 | 923 |
| 2003 | 625 | 1430 |
| 2004 | 535 | 1834 |
| 2005 | 579 | 1921 |
| 2006 | 793 | 2009 |
| 2007 | 910 | 2042 |
| 2008 | 916 | 2328 |
| 2009 | 1101 | 2646 |
| 2010 | 1495 | 3247 |
| 2011 | 1484 | 2903 |
| 2012 | 1705 | 2598 |
| 2013 | 1959 | 2027 |
| 2014 | 1872 | 2040 |
| 2015 | 1668 | 1986 |
| 2016 | 1400 | 1926 |
| 2017 | 1479 | 1778 |
| 2018 | 1315 | 1746 |
| 2019 | 1285 | 1856 |
| 2020 | 1162 | 1662 |
| 2021 | 1010 | 1558 |
| 2022 | 833 | 1542 |
| 2023 | 676 | 1488 |
| 2024 | 722 | 1440 |
| 2025 | 779 | 1318 |
| 2026 | 494 | 932 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin6 Oct 2026US 12,751,960 B2Compass Pathfinder Limited
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- VIPR2 antagonist peptide6 Oct 2026US 12,753,206 B2Ichimaru Pharcos Co., Ltd.
- Antibodies binding to alpha-synuclein for therapy and diagnosis6 Oct 2026US 12,753,223 B2AC Immune SA
- Method of addressing alzheimer's disease or non-alzheimer's dementia8 Oct 2026US 2026/0305670 A1G. Nofar Food Agency Ltd.
- Methods of determining glucose hypometabolism-induced energy crisis and treatments thereof8 Oct 2026US 2026/0306018 A1Senovia Biosciences LLC
- Composition and Method for Topical Trans-spinal Delivery of Nucleic Acids and Small Molecules8 Oct 2026US 2026/0306414 A13P Biotechnologies, Inc.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases, atherosclerosis, hepatitis b infection and human papilloma virus (hpv) infection8 Oct 2026US 2026/0306473 A1
Most cited
By later US patents
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Hybrid immunoglobulins817US 5,116,964 AGenentech, Inc. · 1992
- Process for preparing diaminophenothiazinium compounds687US 8,765,942 B2Provence Technologies · 2014
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005